Recruiting

NCT Number: NCT05038358

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms

Colorectal cancer is the third most common cancer worldwide and its progression-free survival is still low, around 10 months. Thirthy to 50% of patients do not respond to chemotherapy upon initiation of treatment, suggesting that early development of chemoresistance mechanisms remains a major challenge. In order to better characterize these mechanisms, the aim is to develop a model of tumoroids derived from patients with a colorectal tumors prior to any systemic anti cancer treatment. This project will both allow us to study the role of the immunological microenvironment in chemoresistance and identify new predictive markers of tumor response. It will then serve to develop innovative personalized medicine strategies by targeting the newly identified mechanisms. This study should in fine help to improve the cancer patient's care.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Primary Tumor Colon Tumor Colonic Diseases Colonic Neoplasms Colorectal Neoplasms Digestive System Diseases Digestive System Neoplasms Gastrointestinal Diseases Gastrointestinal Neoplasms Intestinal Diseases Intestinal Neoplasms Neoplasms Neoplasms by Site

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

University Hospital of Grenoble Alpes

Grenoble, 38043, France

Location status: Recruiting

Location contact

ARNAUD MILLET, MD,PHD

CONTACT

[email protected]

GAEL ROTH, MD, PHD

CONTACT

[email protected]

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male and female over 18 years old.
Managed at the CHUGA for a colorectal adenocarcinoma
With an indication for immediate surgical resection as part of the care.
Patient naive from neo-adjuvant chemotherapy
Patient did not object to the CRC-ORGA-2 study

Exclusion criteria

Patients protected by law (pregnant or breastfeeding women, minors, patients under guardianship or trusteeship, persons deprived of their liberty or hospitalized under duress).
Patients with positive HIV, HBV, HCV serology.

Treatment and study plan

Primary outcomes

Percentage of viable organoids for 60 days of culture maintenance.

Time frame: 60 days of culture maintenance.

Study contacts

Contact information is provided by the study sponsor or research team.

ARNAUD MILLET, MD, PHD

CONTACT

[email protected]

GAEL ROTH, MD, PHD

CONTACT

[email protected]

04 76 76 51 68 ext. 0033

Sponsors and collaborators

Lead sponsor

University Hospital, Grenoble

Other

Registry information

Official study title

Tumor Immune Microenvironment Involvement in Colorectal Cancer Chemoresistance Mechanisms: a Patient-derived Tumoroids Prospective Collection From Systemic Treatment Naive Tumors

Acronym: CRC-ORGA2

Important dates

Study start: 2022
Primary completion: 2028
Study completion: 2030
First posted: Sep 9, 2021
Registry last updated: May 19, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed